TC BIOPHARM HOLDINGS PLC-ADR (TCBP)
US87807D4007 - ADR
TCBP Advances ACHIEVE Phase 2b Clinical Trial with Final Dosing of 3 Patients
/PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform...
Keep an eye on the top gainers and losers in Wednesday's session, as they reflect the most notable price movements.
Let's take a look at the stocks that are in motion in today's session.
These stocks are moving in today's pre-market session
As the US market prepares to open on Wednesday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.
TCBP Announces General Meeting of Shareholders to Approve One-Time Shareholder Dividend
/PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform...
EXCLUSIVE: Penny Stock TC BioPharm Proposes Special Stock Dividend
On Wednesday, TC BioPharm (Holdings) PLC (NASDAQ:TCBP) announced that its Board of Directors approved a special dividend of 0.25 American Depositary Shares for every 1 ADS held by shareholders, pending shareholder approval. The company intends to hold a general meeting of shareholders on Monday, December 30. The dividend is expected to be declared on December 30, 2024, and payable to shareholders who own the company's stock at the close of trading on January 02, 2025. "We are extremely pleased t
TCBP Partners with CareDx to Support ACHIEVE Clinical Trial Using AlloCell for Pharmacokinetic Monitoring of Allogeneic Cell Therapy
/PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform...
TCBP Provides Quarterly Update on the ACHIEVE (UK) Clinical Trial
/PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform...
TCBP Awarded Non-Dilutive Funding, ScaleReady's G-Rex® Grant
/PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP), a clinical-stage biotechnology company developing platform...
TCBP Provides Shareholder Update and Highlights Recent Milestone Achievements
/PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP), a clinical-stage biotechnology company developing platform...
TCBP Responds to False Social Media Claim
/PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP), a clinical-stage biotechnology company developing platform...
TCBP Enters Research Planning Collaboration with Dr. Carlos Maluquer de Motes for Mpox Therapeutic
/PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP), a clinical-stage biotechnology company developing platform...
TCBP Announces Artificial Intelligence Initiative with Partner Carnegie Mellon University for Donor Screening
/PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP), a clinical-stage biotechnology company developing platform...
TCBP Announces Site Opening of Guys and St. Thomas Hospital
/PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform...
BioMedNewsBreaks — TC Biopharm (Holdings) PLC (NASDAQ: TCBP) Featured at Next Month’s NYC ThinkEquity Conference
TC Biopharm (NASDAQ: TCBP), a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, will be presenting at the ThinkEquity Conference held on Oct. 30, 2024, in New York City. According to the announcement, TC Biopharm CEO Bryan Kobel will be presenting at the conference. During his presentation, Kobel will […]
TCBP to Present at the 2024 ThinkEquity Conference in NYC
/PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform...
TCBP Announces First Patient Completed the Full Dose Regimen in ACHIEVE Clinical Trial
/PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform...
TC BioPharm Intends to Launch Preclinical Studies for Treatment of Monkey Pox
/PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform...
TC BioPharm Intends to Launch Preclinical Studies for Treatment of Monkey Pox
EDINBURGH, Scotland, Sept. 6, 2024 /PRNewswire/ — TC BioPharm (Holdings) PLC (“TC BioPharm” or the “Company”) (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that it intends to begin Proof of Concept preclinical studies for its lead therapeutic TCB 008, for treatment in monkey […]
TC BioPharm Intends to Launch Preclinical Studies for Treatment of Monkey Pox
/PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform...
TCBP Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference
/PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform...
BioMedNewsBreaks — TC Biopharm (Holdings) PLC (NASDAQ: TCBP) Doses Five New Patients in UK ACHIEVE Phase 2b Trial
TC Biopharm (NASDAQ: TCBP), a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, has dosed five new patients in the ongoing ACHIEVE phase 2b trial in the United Kingdom. According to the announcement, that brings the total number of patients dosed to six; five patients have received a second dose and […]
TCBP Announces Dosing of 5 New Patients in ACHIEVE
/PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform...
TC BioPharm Announces Closing of Upsized $6.0 Million Public Offering
/PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform...
TC BioPharm Announces Grant of European Patent Covering Use of Modified Gamma Delta Cells for the Treatment of Cancer and Viral Indications
/PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform...
TC BioPharm Regains Compliance with Nasdaq Listing Rule 5550(b)
/PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform...